Blood-ISBT 2025 is in full swing in Perth, WA. This morning here is Prof. Jean Connors on options to prevent and control bleeding on new FXI inhibitor anticoagulants #Blood2025#THANZ
What a great plenary lecture of Leslie Raffini at #ISTH2025 Pediatric Thrombosis: a lot has been done in 30 years, but still a lot to be done in the coming years!
Observational data (n=506) demonstrating superior safety and efficacy of low dose apixaban compared to VKA in cirrhotic PVT. Even Child C cirrhosis was represented. #ISTH2025@THANZBlood
👏 A truly encouraging session today at the #ISTHCongress on the ISTH haemophilia guidelines. The open and constructive dialogue reflects the progress we’ve made collectively as a global community. This evolving landscape highlights the value of ongoing collaboration and mutual respect among all stakeholders.
@THANZBlood are thrilled that Jean will be one of our keynote speakers at our national Blood conference in Perth in October! Looking forward to it! #ISTH2025#Blood2025
Dr Jean Connors opening up the SSC on Perioperative & Critical Care Thrombosis and Hemostasis. I know how hard she and her cochairs worked on this program! Congratulations!
#ISTH2025
Sustained and stable FIX levels have now been repeatedly been observed across multiple #genetherapy clinical trials for #hemophila B.
Will extend the red line tomorrow at Clinical Gene Therapy session at #ISTH2025.
Critical appraisal of the ISTH Haemophilia Guidelines session, with some robust discussion and interesting perspectives, our very own Dr Jane Mason delivering a great presentation “Dissecting the Guidelines” the clinician experience #ISTH2025@THANZBlood
Promising phase1/2 data on NXT007 prophylaxis presented by Midori Shima at #ISTH2025. Can we achieve “normal range” FVIII equivalence? We look forward to phase 3 studies and further data around ADA risk.
@evsfaustino beautiful summary of 2-hit hypothesis for CVC related VTE in critically ill kids, role of inflammation, need to decouple hemostasis from thrombosis, potential role for XI / XIIa inhibitors, and maybe adolescents aren’t just young adults… #ISTH2025@THANZBlood
Is this the end of rivaroxaban for acute VTE?
@LanaCastellucci presenting the COBBRA trial - 1st RCT comparing apixaban to riva over 3 months.
56% reduction in bleeding risk with apixaban.
A safer Rx with the same efficacy.
#ISTH2025
Dr Uma Athale gave an excellent SOA update on thromboprophylaxis in pediatric cancer ?who, when, with what and for how long…more questions than answers right now! Work to be done #ISTH2025@THANZBlood
Late breaking abstract session at #ISTH2025. COBRRA results are in! 50% reduction in bleeding with Apixaban use for acute VTE compared to Rivaroxaban. @THANZBlood members were co-investigators on this study, an enormous effort.
A fitting tribute to the life’s work of Claire McLintock delivered in the Claire McLintock Memorial Lecture by Jennifer Curnow. Congratulations Jennifer, @THANZBlood is proud of you! #ISTH2025
The #ISTH2025 Opening ceremony is under way! @IsthPresident is giving opening remarks on the importance of global collaboration and knowledge exchange: